Amarin Corporation(US:AMRN) Newsfilter·2024-04-03 12:00Core Viewpoint - Amarin Corporation has received a Decision to Grant from the European Patent Office for a new patent covering VAZKEPA, extending its exclusivity until 2039, which enhances the product's market potential in Europe [1][2]. Patent and Exclusivity Details - The new patent from the EPO will be granted on April 24, 2024, and will cover VAZKEPA in Europe until April 2039, based on the REDUCE-IT cardiovascular outcomes trial [3]. - Amarin successfully defended a separate patent related to VAZKEPA from third-party opposition, which is valid until June 2033 and pertains to reducing cardiovascular death risk [4]. - The existing exclusivity for VAZKEPA includes legacy patent protections from the ANCHOR study, extended via Supplemental Protection Certificates until June 2035, along with regulatory exclusivity until March 2031 [5].